SynthesisGeneral thoracic and cardiovascular surgery2025
Effects of trimetazidine on cardiac function and ventricular remodeling in patients with ischemic cardiomyopathy: a systematic review and meta-analysis.
Synthesis in General thoracic and cardiovascular surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIschemic cardiomyopathy (ICM) is a late manifestation of coronary artery disease, marked by significant deterioration of cardiac pump function and abnormal ventricular remodeling. Current therapies have limitations, driving the search for novel approaches, especially targeting myocardial metabolism, as a key research focus.
objectiveThis study aims to systematically evaluate the effects of Trimetazidine (TMZ) on improving cardiac function and delaying ventricular remodeling in patients with ICM.
methodsRelevant literature was retrieved from five databases: PubMed, Embase, Web of Science, Cochrane Central, and CNKI, covering all studies published to date. A meta-analysis was conducted to assess the impact of trimetazidine on LVEF, E/A ratio, wall motion index, LVEDD, and LVESD, using standardized mean differences (SMD) as the effect measure and calculating the 95% CI.
resultsA total of 9 studies involving 1037 patients were included. The meta-analysis results showed that the LVEF in the trimetazidine treatment group was significantly higher than that in the control group (SMD = 0.64, 95% CI: [0.30, 0.97], p < 0.0001). The E/A ratio and wall motion index also showed improvement (SMD = 0.20, 95% CI: [0.03, 0.36]; SMD = - 0.54, 95% CI: [- 0.78, - 0.29]). However, the effects of trimetazidine on LVEDD and LVESD were not significant (SMD = - 0.36, 95% CI [- 1.09, 0.36]; SMD = - 0.03, 95% CI [- 1.12, 1.07]).
conclusionTMZ can effectively improve cardiac function in patients with ischemic cardiomyopathy, but its impact on ventricular remodeling is limited. Future research should further explore its application in the treatment of ICM.
Indexed as
Identifiers
40526301What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.